Characteristics of patients with and without thrombosis
| Variable . | N . | With thrombosis (n = 28) . | Without thrombosis (n = 30) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | Mean . | SD . | n . | Mean . | SD . | |||
| Age, y | 55.9 | 18.5 | 65.6 | 12.1 | ||||
| Sex | ||||||||
| Male | 29 | 12 | 17 | |||||
| Female | 29 | 16 | 13 | |||||
| Diagnosis | ||||||||
| PV | 39 | 19 | 20 | |||||
| ET | 19 | 9 | 10 | |||||
| Laboratory tests | ||||||||
| White blood cell count, × 109/L | 10.4 | 9.3 | 6.9 | 3.3 | .076 | |||
| Hemoglobin, g/dL | 15.1 | 6.3 | 14.7 | 2.5 | .764 | |||
| Platelets, × 109/L | 648.0 | 597.8 | 470.4 | 330.6 | .173 | |||
| Patients with JAK2V617F mutation | 27 | 23 | ||||||
| JAK2V617F allelic burden | 50 | 39.8 | 37.3 | 19.8 | 20.9 | .022 | ||
| Thrombosis type | NA | |||||||
| Venous | 22 | |||||||
| Arterial | 6 | |||||||
| Medications* | ||||||||
| Aspirin | 3 | 19 | ||||||
| Warfarin | 14 | — | ||||||
| Rivaroxaban | 2 | — | ||||||
| Aspirin plus clopidogrel | 2 | — | ||||||
| Statins | 4 | 9 | ||||||
| NSAIDs | — | 2 | ||||||
| Hydroxyurea | 11 | 13 | ||||||
| Pegylated IFN-α | 9 | 7 | ||||||
| Ruxolitinib | 2 | 1 | ||||||
| Busulfan | 1 | — | ||||||
| Variable . | N . | With thrombosis (n = 28) . | Without thrombosis (n = 30) . | P . | ||||
|---|---|---|---|---|---|---|---|---|
| n . | Mean . | SD . | n . | Mean . | SD . | |||
| Age, y | 55.9 | 18.5 | 65.6 | 12.1 | ||||
| Sex | ||||||||
| Male | 29 | 12 | 17 | |||||
| Female | 29 | 16 | 13 | |||||
| Diagnosis | ||||||||
| PV | 39 | 19 | 20 | |||||
| ET | 19 | 9 | 10 | |||||
| Laboratory tests | ||||||||
| White blood cell count, × 109/L | 10.4 | 9.3 | 6.9 | 3.3 | .076 | |||
| Hemoglobin, g/dL | 15.1 | 6.3 | 14.7 | 2.5 | .764 | |||
| Platelets, × 109/L | 648.0 | 597.8 | 470.4 | 330.6 | .173 | |||
| Patients with JAK2V617F mutation | 27 | 23 | ||||||
| JAK2V617F allelic burden | 50 | 39.8 | 37.3 | 19.8 | 20.9 | .022 | ||
| Thrombosis type | NA | |||||||
| Venous | 22 | |||||||
| Arterial | 6 | |||||||
| Medications* | ||||||||
| Aspirin | 3 | 19 | ||||||
| Warfarin | 14 | — | ||||||
| Rivaroxaban | 2 | — | ||||||
| Aspirin plus clopidogrel | 2 | — | ||||||
| Statins | 4 | 9 | ||||||
| NSAIDs | — | 2 | ||||||
| Hydroxyurea | 11 | 13 | ||||||
| Pegylated IFN-α | 9 | 7 | ||||||
| Ruxolitinib | 2 | 1 | ||||||
| Busulfan | 1 | — | ||||||
Common comorbidities for patients with thrombosis included portal hypertension, gastroesophageal reflux disease, and hypothyroidism; for patients without thrombosis, they included hypertension, gastroesophageal reflux disease, and diabetes.
NA, not applicable; NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation.
Comorbidities and medications are reported at the time of sample collection.